These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 18727614)

  • 1. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
    Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy.
    Maggio M; Blackford A; Taub D; Carducci M; Ble A; Metter EJ; Braga-Basaria M; Dobs A; Basaria S
    J Androl; 2006; 27(6):725-8. PubMed ID: 16775253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
    Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
    Lage MJ; Barber BL; Markus RA
    Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
    Collier A; Ghosh S; McGlynn B; Hollins G
    Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.